Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
248.66
-0.01 (0.00%)
May 19, 2025, 4:00 PM - Market closed
Bio-Rad Laboratories Market Cap
Bio-Rad Laboratories has a market cap or net worth of $6.77 billion as of May 20, 2025. Its market cap has decreased by -13.42% in one year.
Market Cap
6.77B
Enterprise Value
6.48B
1-Year Change
-13.42%
Ranking
Category
Stock Price
$248.66
Market Cap Chart
Since December 1, 1998, Bio-Rad Laboratories's market cap has increased from $261.00M to $6.77B, an increase of 2,492.60%. That is a compound annual growth rate of 13.08%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 16, 2025 | 6.77B | -26.42% |
Dec 31, 2024 | 9.20B | -2.27% |
Dec 29, 2023 | 9.41B | -24.96% |
Dec 30, 2022 | 12.54B | -44.52% |
Dec 31, 2021 | 22.61B | 29.99% |
Dec 31, 2020 | 17.39B | 56.99% |
Dec 31, 2019 | 11.08B | 59.20% |
Dec 31, 2018 | 6.96B | -2.05% |
Dec 29, 2017 | 7.10B | 31.92% |
Dec 30, 2016 | 5.38B | 32.52% |
Dec 31, 2015 | 4.06B | 16.39% |
Dec 31, 2014 | 3.49B | -1.57% |
Dec 31, 2013 | 3.55B | 19.03% |
Dec 31, 2012 | 2.98B | 10.33% |
Dec 30, 2011 | 2.70B | -6.45% |
Dec 31, 2010 | 2.89B | 8.90% |
Dec 31, 2009 | 2.65B | 28.98% |
Dec 31, 2008 | 2.06B | -26.11% |
Dec 31, 2007 | 2.78B | 27.31% |
Dec 29, 2006 | 2.18B | 27.59% |
Dec 30, 2005 | 1.71B | 15.63% |
Dec 31, 2004 | 1.48B | 0.60% |
Dec 31, 2003 | 1.47B | 50.86% |
Dec 31, 2002 | 975.80M | 23.39% |
Dec 31, 2001 | 790.80M | 99.29% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 679.94B |
Johnson & Johnson | 364.11B |
AbbVie | 325.05B |
Novo Nordisk | 282.81B |
UnitedHealth Group | 264.80B |
Abbott Laboratories | 234.53B |
Novartis AG | 213.43B |
AstraZeneca | 212.39B |